GIBSON DUNN

Gibson Dunn Advises XOMA Royalty on Acquisition of Mural Oncology

Firm News | August 21, 2025

Gibson Dunn is advising XOMA Royalty Corporation on its acquisition of Mural Oncology plc.

XOMA Royalty is a publicly traded biotech royalty aggregator. Mural Oncology is a biopharmaceutical company focused on discovering and developing immunotherapies for patients with cancer.

Our corporate team is led by partners Ryan Murr and Branden Berns and includes associates Evan Shepherd, Maggie Zhang, and Cody Wong. Partner Pamela Lawrence Endreny and associate Elizabeth Johnson are advising on tax. Partner Cassandra Gaedt-Sheckter and associate Michael Roberts are advising on privacy.

Related People

Ryan A. Murr

Branden C. Berns

Evan Shepherd

Cody Wong

Pamela Lawrence Endreny

Cassandra L. Gaedt-Sheckter

Related Capabilities

Life Sciences

Mergers and Acquisitions

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**